Financial Comparison of Ultragenyx Pharmaceutical and Immunome
What happened
A comparison of Ultragenyx Pharmaceutical and Immunome showed differences in financial metrics, including revenue, earnings per share, and valuation. Immunome has higher earnings but lower revenue than Ultragenyx Pharmaceutical. Immunome is trading at a lower price-to-earnings ratio, while Ultragenyx Pharmaceutical has a consensus target price of $34.58, suggesting a potential upside of 138.31% according to one report.
From dailypolitical.com
Why it matters
The comparison highlights differing risk profiles for the two companies; Immunome has a beta of 2.13, indicating its share price is 113% more volatile than the S&P 500. Conversely, Ultragenyx Pharmaceutical has a beta of 0.31, suggesting its share price is 69% less volatile than the S&P 500.
From dailypolitical.com
Who's involved
- Ultragenyx PharmaceuticalBiopharmaceutical company whose stock is being compared and regulated by the FDA.
Keep exploring
The entities involved
-
Ultragenyx Pharmaceutical
biopharmaceutical company based in Novato, California, United States
Nothing else this week.